Publications by authors named "Debra Scarlata"

Claim this Profile
B
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
John J V McMurray, Inder S Anand, Rafael Diaz, Aldo P Maggioni, Christopher O'Connor, Debra Scarlata

Eur J Heart Fail· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of anemia with darbepoetin alfa in heart failure.
William T Abraham, Inder S Anand, Marc Klapholz, Piotr Ponikowski, Debra Scarlata

Congest Heart Fail· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
Michelle W Krause, Rasib Raja, Anil Agarwal, Marcia R Silver, Debra Scarlata

Drugs Aging· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Gretchen M Brophy, Valerie Sheehan, Marc J Shapiro, Lawrence Lottenberg, Debra Scarlata

Clin Ther· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis.
Ali K Abu-Alfa, Lance Sloan, Chaim Charytan, Mohamed Sekkarie, Debra Scarlata

Curr Med Res Opin· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Joachim Hertel, Harold Locay, Debra Scarlata, Lynnae Jackson, Radha Prathikanti

Am J Nephrol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Jeffrey Hoggard, Thomas Crouch, Stephen McMurray, Michael Levine, Radha Prathikanti, Debra Scarlata

Curr Med Res Opin· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Joachim E W Hertel, Harold R Locay, Debra S Scarlata, Radha Prathikanti, Paul K Audhya

Mayo Clin Proc· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of multidisciplinary, early renal education on vascular access placement.
Jill S Lindberg, Fred E Husserl, Jamie L Ross, Dina Jackson, Debra Scarlata

Nephrol News Issues· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.
David C Dale, Tammy E Cottle, Carol J Fier, Audrey Anna Bolyard, Mary Ann Bonilla, Debra Scarlata

Am J Hematol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis